Summit Therapeutics’ (SMMT) Overweight Rating Reaffirmed at Cantor Fitzgerald

Summit Therapeutics (NASDAQ:SMMT – Get Free Report)‘s stock had its “overweight” rating reiterated by equities researchers at Cantor Fitzgerald in a research report issued on Wednesday,Benzinga reports. A number of other analysts have also commented on the stock. Evercore ISI began coverage on shares of Summit Therapeutics in a research report on Wednesday, March 12th. […]